CA2714833A1 - Vaccins contre l'infection due a l'escherichia coli o157 - Google Patents

Vaccins contre l'infection due a l'escherichia coli o157 Download PDF

Info

Publication number
CA2714833A1
CA2714833A1 CA2714833A CA2714833A CA2714833A1 CA 2714833 A1 CA2714833 A1 CA 2714833A1 CA 2714833 A CA2714833 A CA 2714833A CA 2714833 A CA2714833 A CA 2714833A CA 2714833 A1 CA2714833 A1 CA 2714833A1
Authority
CA
Canada
Prior art keywords
coli
composition
serum
antibodies
specific polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2714833A
Other languages
English (en)
Inventor
Edward Konadu (Deceased)
Shousun C. Szu
John B. Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to CA2714833A priority Critical patent/CA2714833A1/fr
Publication of CA2714833A1 publication Critical patent/CA2714833A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2714833A 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157 Abandoned CA2714833A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2714833A CA2714833A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US1998/014976 WO2000004922A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157
CA2714833A CA2714833A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157
CA2338093A CA2338093C (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2338093A Division CA2338093C (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Publications (1)

Publication Number Publication Date
CA2714833A1 true CA2714833A1 (fr) 2000-02-03

Family

ID=22267510

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2338093A Expired - Fee Related CA2338093C (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157
CA2714833A Abandoned CA2714833A1 (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2338093A Expired - Fee Related CA2338093C (fr) 1998-07-20 1998-07-20 Vaccins contre l'infection due a l'escherichia coli o157

Country Status (4)

Country Link
AU (1) AU767047B2 (fr)
BR (1) BR9815953A (fr)
CA (2) CA2338093C (fr)
WO (1) WO2000004922A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
EP1993604B1 (fr) 2006-03-17 2015-12-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Procédé de préparation de conjugués immunogéniques multivalents complexes
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
EP0911036A3 (fr) * 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Structure immunogene à double vecteur
CA2171942C (fr) * 1993-09-22 2010-12-14 Andrew Lees Methode d'activation de carbohydrate soluble, utilisant de nouveaux reactifs de cyanylation pour l'obtention de constructions immunogenes

Also Published As

Publication number Publication date
WO2000004922A1 (fr) 2000-02-03
CA2338093C (fr) 2010-11-30
CA2338093A1 (fr) 2000-02-03
AU8575898A (en) 2000-02-14
BR9815953A (pt) 2001-03-06
AU767047B2 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
US8168195B2 (en) Vaccines against Escherichia coli O157 infection
Alexander et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses
AU669854B2 (en) Escherichia coli O-polysaccharide-protein conjugate vaccine
CN108430500B (zh) 用于针对肠外致病性大肠杆菌的免疫保护的方法和组合物
AU706479B2 (en) Antigenic group B streptococcus type II and type III polysaccharide fragments having A 2, 5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
WO2000033882A1 (fr) Conjugue vaccinal vi-repa pour l'immunisation contre la salmonella typhi
US8202520B2 (en) Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
EP0787015B1 (fr) Synthese du vaccin antityphoidique a partir d'un polysaccharide de plante ou de fruit
AU678549B2 (en) Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
US9173932B2 (en) Vibrio cholerae O139 conjugate vaccines
CA2338093C (fr) Vaccins contre l'infection due a l'escherichia coli o157
Wu et al. Investigation of nontypeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines
Liao et al. Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi
Szu et al. Vaccines for prevention of enteric bacterial infections caused by Salmonellae
Schneerson et al. VACCINES FOR PREVENTION OF ENTERIC BACTERIAL INFECTIONS CAUSED BY SALMONELLAE

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20170420